Business
Brii Biosciences Provides Corporate Updates and Reports 2025 Interim Financial Results
Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical need, today provided a corporate update and reported its financial results for the six-month period ended June 30, 2025.
About this update from Brii Biosciences Limited
[{"type":"text","content":"Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy","length":72,"tagName":"p","attribs":{}},{"type":"text","content":"Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin","length":105,"tagName":"p","attribs":{}},{"type":"text","content":"Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy","length":83,"tagName":"p","attribs":{}},{"type":"text","content":"Conference Calls Scheduled: English Session: August 21 at 9:00 p.m. HKT / 9:00 a.m. ET Chinese Session: August 22 at 9:00 a.m. HKT / August 21 at 9:00 p.m. ET","length":170,"tagName":"p","attribs":{}},{"type":"text","content":"DURHAM, N.C., and BEIJING, Aug. 21, 2025 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio," or the "Company," stock code: 2137.HK), a biotechnology company developing therapies to improve patient health across diseases with high unmet medical need, today provided a corporate update and reported its financial results for the six-month period ended June 30, 2025.","length":391,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Brii Biosciences Limited)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Brii Biosciences Limited)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":105,"url":"https://media.zenfs.com/en/prnewswire.com/a19981213a11806c724bc1d308aaae78"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/V3nK_VGVGa.vonDXTWY9Ug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE4NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/a19981213a11806c724bc1d308aaae78","width":400,"height":105}},"href":"https://mma.prnewswire.com/media/1690538/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"In the first half of 2025, Brii Bio rapidly advanced its core hepatitis B virus (HBV) functional cure program through multiple confirmatory Phase 2b trials, including ENRICH and ENHANCE studies, seeking combination regimens with higher HBV functional cure rates. Encouraged by promising data from Cohort 4 of the ENSURE study, presented at both the Asian Pacific Association for the Study of the Liver (APASL) and the European Association for the Study of the Liver (EASL) Congress 2025 supporting the potential of its patient enrichment strategy through BRII-179 induced anti-...